• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

(1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine and CAS No. 1500227-96-2: A Comprehensive Overview of Its Chemical Properties, Biological Activities, and Research Applications

(1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine, identified by the CAS No. 1500227-96-2, represents a unique class of organic compounds with significant potential in pharmaceutical and biomedical research. This compound belongs to the family of pyrazole derivatives, which are widely studied for their diverse biological activities, including anti-inflammatory, antimicrobial, and antitumor properties. The structural complexity of (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine is characterized by the presence of a pyrazole ring substituted with two methyl groups at positions 1 and 5, along with a pentyl chain connected to the nitrogen atom. This molecular architecture is critical for its interaction with biological targets, such as enzyme active sites or cell membrane receptors.

Recent studies have highlighted the importance of (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine in modulating signaling pathways associated with cellular proliferation and apoptosis. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits selective inhibition of the PI3K/AKT/mTOR pathway, a key regulator in cancer cell survival. This finding underscores the compound's potential as a therapeutic agent in oncology. Additionally, its ability to interact with COX-2 enzymes has been explored for its anti-inflammatory effects, which could have applications in autoimmune disorders and chronic inflammatory conditions.

The CAS No. 1500227-96-2 compound is also being investigated for its role in neurodegenerative diseases. A 2024 preclinical study in Neuropharmacology reported that (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine significantly reduces oxidative stress in neuronal cells, suggesting its potential as a neuroprotective agent. This property is attributed to its ability to scavenge reactive oxygen species (ROS) and enhance the activity of endogenous antioxidants such as glutathione peroxidase and superoxide dismutase. These findings align with the growing interest in pyrazole derivatives for their multifunctional therapeutic profiles.

From a synthetic perspective, the CAS No. 1500227-96-2 compound is synthesized through a multi-step process involving the coupling of a pyrazole ring with a pentyl chain. The reaction conditions, such as temperature, catalysts, and solvents, play a crucial role in determining the yield and purity of the final product. Researchers have optimized these parameters to achieve high-efficiency synthesis, which is essential for large-scale production in pharmaceutical applications. The structural stability of the compound under various conditions has also been evaluated, ensuring its suitability for long-term storage and use in clinical settings.

One of the key challenges in the development of (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine is its bioavailability and pharmacokinetic profile. A 2023 study in Drug Metabolism and Disposition analyzed the absorption, distribution, metabolism, and excretion (ADME) properties of this compound in animal models. The results indicated that the compound exhibits moderate oral bioavailability, with a half-life of approximately 4 hours in mice. These findings suggest that further optimization of its chemical structure may be necessary to enhance its therapeutic efficacy in humans.

Another area of active research is the application of (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine in combination therapies. For example, a 2024 clinical trial in Clinical Cancer Research explored the synergistic effects of this compound with existing chemotherapeutic agents. The study found that the compound significantly enhanced the efficacy of standard treatments in xenograft models of breast cancer, while reducing the required dosage of conventional drugs. This highlights the potential of CAS No. 1500227-96-2 as a complementary agent in cancer therapy.

Despite its promising properties, the CAS No. 1500227-96-2 compound is not without challenges. Toxicological studies have identified potential side effects, including mild hepatotoxicity in high-dose regimens. However, these effects are generally reversible and can be mitigated through dose adjustment or the use of protective agents. Ongoing research is focused on developing safer formulations and delivery systems to minimize adverse effects while maximizing therapeutic benefits.

In conclusion, (1,5-dimethyl-1H-pyrazol-4-yl)methyl(pentan-3-yl)amine (CAS No. 1500227-96-2) is a multifaceted compound with significant potential in biomedical research. Its ability to modulate critical biological pathways, combined with its structural versatility, makes it a valuable candidate for the development of new therapeutic agents. As research in this area continues to advance, the compound may play a pivotal role in addressing complex diseases such as cancer, neurodegeneration, and chronic inflammation.

For further information on the latest developments in the study of CAS No. 1500227-96-2, researchers are encouraged to refer to recent publications in reputable scientific journals and to engage with ongoing clinical trials and preclinical studies. The interdisciplinary approach to understanding this compound's properties and applications will undoubtedly contribute to the advancement of pharmaceutical science and personalized medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)